78 results about "Tumor imaging" patented technology

The invention relates to the technical field of nuclide probes, and discloses a targeted PARP nuclide probe and a preparation method and application thereof, and the targeted PARP nuclide probe comprises a radionuclide labeled compound as shown in formula I; the targeted PARP nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high PARP protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The invention discloses a gamma-glutamyl transpeptidase catalytic hydrolysis induced charge upset polymer, which contains a gamma-glutamyl transpeptidase response element part and a fluorescent probe corresponding fragment part, the invention also discloses a preparation method of the polymer for turning charge by catalytic hydrolysis of gamma-glutamyltranspeptidase and an application method of the polymer in the field of tumor imaging. According to the present invention, the gamma-glutamyltranspeptidase catalytic hydrolysis electric charge overturning polymer is adopted as the response type tumor imaging probe, such that the electric charge can be converted from the negative or neutral state to the positive state so as to achieve the rapid uptake of the positively charged polymer by the tumor cells so as to achieve the rapid spraying imaging, and the probe response after the uptake is adopted so as to achieve the rapid spraying imaging; the imaging effect of the probe on the tumor is greatly improved, and the probe has important significance in solid tumor imaging for assisting a doctor in surgical resection.

The invention relates to the technical field of biology, and particularly discloses a tumor imaging biomarker quantitative analysis system based on multi-mode MRI voxel space coupling and application. According to the application, the spatial coupling relationship between blood brain barrier destruction and perfusion in a tumor can be quantitatively reflected through the voxel overlap region proportion of T1CE and CBF signals, the 1p / 19q state can be efficiently predicted, and accurate prediction of IDH mutation and WHO grading (2-3 grade vs.4 grade) is realized in cooperation with clinical factors, so that the application has a wide application prospect. And an efficient and potential noninvasive imaging biomarker is provided for ADG preoperative molecular typing and grading prediction.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

This invention discloses an ERβ-targeted hydrogen peroxide-responsive near-infrared fluorescent probe, its preparation method, and its applications, belonging to the field of medical technology. The fluorescent probes of this invention are dicyanomethylene-4H-benzodihydropyran compounds P1 and P2 containing borate ester groups, with the following structural formula. These fluorescent probes use DCM-OH as a backbone, acting as both a fluorophore and an ERβ ligand. The borate ester group is the H2O2 responsive group. The introduction of the borate ester group disrupts the push-pull effect of the DCM-OH fluorophore, preventing fluorescence emission. However, in a high-concentration H2O2 environment, the borate ester group is specifically cleaved by H2O2, subsequently exhibiting strong initiation fluorescence and enabling tumor imaging in vitro and in vivo. This invention brings new opportunities for the diagnosis and research of prostate cancer.

The present invention discloses a polythiocarbamate, its preparation method, and application. The structural formula of the polythiocarbamate of the present invention is: wherein m is a natural number between 110 and 117, and n is a natural number between 6 and 17. The polythiocarbamate of the present invention has excellent biocompatibility and degradability. It can self-assemble in aqueous phase to form nanoparticles and be used as a transport vehicle for fluorescent probes and hydrophobic anticancer drugs. It can specifically amplify H2S signals at tumor sites and can be used for efficient and highly selective tumor imaging and treatment, possessing great potential for clinical application.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

The present application relates to the technical field of cancer detection, in particular to a kind of tumor imaging guided photodynamic therapy reagent.The reagent is named ADS254BE / H2TPP NPs, which is composed of hydrophobic conjugated polymer ADS254BE and tetraphenylporphyrin H2TPP doped polymer microspheres, and the surface of the polymer microspheres also has PSMA modification layer.The reagent is prepared by uniformly mixing ADS254BE, H2TPP and PSMA solution, ultrasonic treatment, room temperature standing, and then evaporating solvent in the solution.The photodynamic diagnosis and treatment reagent provided by the present application shows bright red emission centered at 650nm, relatively large stoke shift, higher singlet oxygen generation rate, and good light stability and biocompatibility.The present application provides a feasible strategy for constructing new optical diagnosis and treatment integrated reagent, and is expected to promote the development of imaging guided photodynamic therapy.

The invention discloses an enzyme-activated fluorescent molecular precursor as well as a preparation method and application thereof. The enzyme-activated fluorescent molecular precursor has a chemical structure as shown in a formula I which is described in the specification. The invention develops an enzyme-activated fluorescent molecular precursor which can be used for real-time imaging of tumors by targeting exogenous enzyme to the tumors and specifically activating a probe at the tumors; according to the invention, the exogenous enzyme is introduced as an activation trigger, and normal cells do not have the exogenous enzyme, so that the problem of co-expression of the endogenous enzyme in non-tumor tissues can be avoided, background fluorescence signals can be reduced to the greatest extent, and the imaging specificity and accuracy are remarkably improved.

This invention discloses a water-soluble melanin CEST contrast agent, its preparation method, and its application, relating to the field of magnetic resonance imaging contrast agent technology. This contrast agent, its preparation method, and its application aim to solve the technical problem that existing contrast agents containing paramagnetic metals can damage liver and kidney function. This water-soluble melanin CEST contrast agent comprises the following components by weight: 2-3 parts ammonia, 40 parts ethanol, 100 parts deionized water, and 0.5 parts reaction substrate. The chemical shift corresponding to this contrast agent preparation method is 4.0 ppm, exhibiting good adaptability to acidic environments and suitability for use in the tumor microenvironment. It is polymerized using dopamine hydrochloride or 3,4-dihydroxyphenylalanine, with inexpensive, simple, and readily available raw materials, simple synthesis, and easy large-scale preparation. It achieves tumor imaging without the need for paramagnetic metal ions, avoiding the damage to liver and kidney function caused by heavy metal ions.

An arylboron compound, its preparation method, applications, and pharmaceutical compositions are disclosed for tumor imaging. The compound of formula (I) exhibits high fluorescence quantum efficiency through intramolecular charge transfer. The compound of formula (I) synthesized in this invention can be linked to different antibodies via Q3 at certain concentrations, allowing for precise targeting of corresponding tumors based on the antibody. This type of boron drug formulation can be used in boron neutron capture therapy to kill tumor cells. It exhibits better killing effects; the compound of formula (I) targets tumor cells through antigen-antibody interaction. After the boron-10-containing drug accumulates at the tumor site, neutron radiation triggers a nuclear reaction releasing alpha particles and... 7 Lithium particles kill cells; the range of these two particles is approximately 10 μm. High-energy-density heavy ions disrupt the DNA double helix structure in tumor cells, causing irreparable cell death. Simultaneously, the 10 μm distance avoids damage to normal cells and tissues.

The invention belongs to the technical field of artificial intelligence assisted medical treatment, and particularly relates to a PET / CT tumor imaging examination result prediction system based on a large language model. The system comprises an input module used for inputting information of a patient; the prediction module is used for analyzing the information of the patient according to the large language model to obtain a prediction result that the patient is possibly positive in PET / CT tumor imaging examination; and the output module is used for outputting the prediction result. The method can assist a doctor in deciding whether a patient needs to be subjected to PET / CT examination or not, so that the PET / CT examination is more reasonable, and the positive rate of the PET / CT examination is effectively improved. Therefore, the method has a good application prospect.

The application discloses a FAPI derivative containing 4-cyano thiazolidine modification and application thereof, relates to the field of drug compounds for diagnosing tumors, and provides a FAPI derivative containing 4-cyano thiazolidine modification, a chemical structural formula of which is shown as formula I. The FAPI derivative has good stability, is simple to prepare, has high radiochemical purity and good biological performance, and can be further used for clinical PET / CT tumor imaging, effectively solving the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes. 18 The FAPI derivative containing 4-cyano thiazolidine modification can solve the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes, and make up for the defects of the prior art.

We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

The present application relates to the field of biological medicine, and provide a kind of targeting PSMA dimer compound and its derivative and application, the structure general formula of the dimer compound is as shown in formula (I).The dimer compound and its derivative of the present application have very high affinity and targeting to PSMA, after being labeled with suitable radionuclide, can be used as nuclear medicine molecular probe, to realize early diagnosis, staging and treatment of prostate cancer, 68 Ga]diPSMA-1-DOTA showed good tumor uptake in PET imaging of tumor mice.Therefore, this kind of radioactive complex has good clinical application prospect in tumor imaging targeting PSMA (especially PET imaging), and lays an important foundation for the radiotherapy application of [ 177 Lu]diPSMA-1-DOTA and [ 225 Ac]diPSMA-1-DOTA.

The application belongs to the field of fluorescent probes, and particularly relates to a tumor-targeting photothermal reagent based on fluoro-rhodamine, and a preparation method and application thereof. To solve the problems that most of existing photothermal reagents have difficulty in post-modification due to complex synthesis, poor biological compatibility due to large molecular weight, and lack of tumor targeting of these molecules, and generally need to be made into nanoparticles to enrich to the tumor site by EPR effect, the application develops a tumor-targeting photothermal reagent Tag-880-NHS based on fluoro-rhodamine, which has the characteristics of simple synthesis, good water solubility, good light stability, high photothermal conversion efficiency, and an absorption wavelength located in the NIR region, and can be used for labeling a specific targeting epidermal growth factor monoclonal antibody-panitumumab, and can be used in the fields of tumor imaging and treatment, and has important application value.

The invention provides a real-time dynamic MRI (Magnetic Resonance Imaging) tumor imaging method and system based on compressed sensing, and relates to the technical field of medical imagines.The method comprises the following steps: acquiring two types of weighted image dynamic signal data generated by a detection device at different time points due to structural transformation through a compressed sensing technology; a multi-echo water-fat separation sequence is adopted for dynamic scanning, signals are separated according to water-fat chemical shift differences, and an initial water diagram and a non-water phase diagram are reconstructed and generated; performing time resolution analysis in combination with the dynamic signal data and the two types of images, generating a signal intensity curve of the detection device, and separating a specificity enhancement signal; and finally, in combination with the time dimension information, reconstructing the image by using a compressed sensing algorithm to obtain a dynamic enhanced image representing the target tissue, and according to the application, the artifacts are inhibited through the time evolution mode of the detection device, so that accurate real-time dynamic MRI tumor imaging can be realized.

The invention relates to the technical field of nuclide probes, and discloses a COX-2 targeting nuclide probe as well as a preparation method and application thereof, and the COX-2 targeting nuclide probe comprises a radionuclide labeled compound as shown in a formula I; the targeting COX-2 nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high COX-2 protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The invention discloses a nuclide-labeled compound targeting PSMA-TATE double targets as well as a preparation method and application of the nuclide-labeled compound. The nuclide-labeled compound is DOTA-PSMA-TATE labeled by < 68 > Ga or < 177 > Lu. The < 68 > Ga and < 177 > Lu labeled PSMA-TATE targeted double-target tumor developer provided by the invention is stable in property and good in imaging effect, and has high affinity and specificity to PSMA and TATE, and further preclinical animal experiment research proves that < 68 > Ga-DOTA-PSMA-TATE is expected to become a broad-spectrum tumor developer with a good application prospect, and < 177 > Lu-DOTA-PSMA-TATE is expected to become a treatment means.

The application relates to the field of organic chemistry and high polymer chemistry, in particular to a functionalized double-block copolymer and a preparation method and application thereof. The application provides a functionalized double-block copolymer, and a chemical structural formula of the functionalized double-block copolymer is shown as formula I. The functionalized double-block copolymer or polymer particle provided by the application can be widely applied in the fields of tumor imaging and tumor treatment, and has not only good safety, realizes faster and adjustable (by changing the number of pipe groups) degradation and removal of the polymer under an acidic condition, but also has excellent specific high-quality imaging effects at a target site, has characteristics of high signal-to-noise ratio, clear boundary, long half-life and the like, solves the problem of real-time intraoperative navigation of the fluorescence imaging technology, and thus has good industrialization prospects.

The present application relates to a kind of tyrosine derivatives and its preparation method, preparation raw materials and application.The above-mentioned tyrosine derivative has the following structural formula:Experimental demonstration, the above-mentioned tyrosine derivative is introduced by deuterium in traditional 18 F-tyrosine, which can improve the imaging target ratio and enhance the sensitivity of tumor imaging when used for the preparation of imaging agents.

The invention discloses a charge-assisted targeting cyclodextrin carrier molecule as well as a preparation method and application thereof, the cyclodextrin carrier molecule integrates cyclodextrin, an M2pep ligand and a pH response group through chemical connection to obtain a biologically safe carrier with a clear structure and simple components. The carrier molecule is used for loading a drug and constructing nanoparticles, and cyclodextrin is responsible for loading a fluorescent dye or a nuclear drug; the M2pep ligand provides an active targeting function for the tumor; on one hand, the pH response group adjusts the surface charge of the nano-particles to enable the nano-particles to be negatively charged and prolong the blood circulation time of the medicine, and on the other hand, the nano-particles respond to an acidic tumor microenvironment and are switched into positive charges to enhance the tumor targeting of the nano-particles. In addition, the nano-particles also have the characteristics of quickly developing tumors, retaining in the tumors for a long time and quickly removing in normal organs, so that the technical problems of low tumor drug delivery efficiency and more non-target organ accumulation in the prior art are solved.

The application discloses a kind of high specificity tumor imaging fluorescent probe, preparation method and application thereof, belong to fluorescent probe technical field, the structural formula of the fluorescent probe is as shown in formula III, formula IV: compared with the specificity fluorescent probe that currently exists, high specificity tumor imaging fluorescent probe III and IV will tumor growth attack system and tumor defense system combination, without introducing bulky targeting group in molecule, also do not need to obtain specific site by a large number of screening, with better performance-price ratio.Compared with the fluorescent probe I and II without being improved, high specificity tumor imaging fluorescent probe can effectively realize the distinction of normal cells and tumor cells at cell level.

This invention discloses an RNA-reactive fluorescent probe, its preparation method, and its application in tumor imaging and treatment. Upon response to ALP enzyme, the probe exhibits enhanced fluorescence, with a corresponding increase in photoacoustic intensity at 685 nm. Simultaneously, after enzyme response, the probe reacts with cytoplasmic RNA under red light irradiation, prolonging its residence time in tumor cells and achieving long-window tumor imaging. More importantly, this cross-linking reaction causes mitochondrial damage, leading to severe tumor cell apoptosis and thus inhibiting tumor growth. This invention's probe not only enables long-window near-infrared and photoacoustic dual-modal imaging of tumors but, more importantly, inhibits tumor growth, achieving integrated tumor diagnosis and treatment.

This invention relates to the field of molecular probe technology, and more particularly to a near-infrared fluorescent probe, its preparation method, and its applications. The near-infrared fluorescent probe provided by this invention has the structure shown in Formula I. Through click chemical bridging, it enables convenient enrichment and identification of covalently targeted proteins, thereby simultaneously achieving high-sensitivity tumor imaging and in-depth proteomics analysis. The near-infrared fluorescent probe provided by this invention not only retains and optimizes the high-contrast tumor imaging capabilities of IR-780, but also serves as a highly efficient chemical proteomics tool, systematically revealing its target map and binding mechanism. Ultimately, it forms a platform technology integrating bright pan-tumor labeling and functional proteomics analysis, providing a solution to overcome tumor heterogeneity and advance the rational design of probes.

The present invention discloses H2O2 responsive crosslinking NIR molecular probe for tumor microenvironment and application therefor. The preparation method includes the following steps: the amide condensation of 2-propynylamine and Fmoc-Lys(Boc)-OH to obtain compound A01-01; removing protecting groups from compound A01-01, to obtain compound C1-2; reacting compound C1-2 and NHS-activated (3-carboxypropyl)triphenylphosphonium bromide, to obtain compound C1-3; removing protecting groups from compound C1-3, to obtain compound C1-4; reacting compound C1-4 with NHS-activated 3,5-dioxocyclohexane carboxylic acid, to obtain a compound C1-5; and reacting compound C1-5 with NIR dye, to obtain a H2O2 responsive crosslinking NIR molecular probe for tumor microenvironment. The probe itself uses H2O2 in a tumor microenvironment for crosslinking on a tumor site, achieving the goal of a long-term retention, thereby improving a result of tumor imaging, and providing a novel strategy and means for improving long-term retention of a NIR molecular probe at a tumor site.

The invention discloses a radionuclide-labeled small-molecule inhibitor targeting RANKL, a precursor compound thereof, a preparation method and application, and belongs to the technical field of nuclear medicine. The invention discloses a precursor compound with a structure as shown in a formula I or pharmaceutically acceptable salt thereof, and a radionuclide-labeled small-molecule inhibitor targeting RANKL with a structure as shown in a formula II or pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compounds as shown in the formula I and the formula II, and application of the compounds in preparation of tumor imaging agents. Or / and application in preparation of drugs for treating tumors. According to the invention, a chelating agent DOTA is creatively combined with a small molecule compound to synthesize a novel compound as shown in a formula I; according to the present invention, the nuclide-labeled compound represented by the formula I can effectively provide the RANKL / RANK signal pathway targeting potential, and can be used for imaging and treatment of related diseases.

The invention discloses an LAT-1 specific targeting probe designed on the basis of a molecular docking technology and application of the LAT-1 specific targeting probe in tumor imaging, and particularly relates to a gold nanocluster (Met-Phe-AuNCs) modified on the basis of methionine-phenylalanine double ligands and a preparation method and application of the gold nanocluster (Met-Phe-AuNCs). The nanocluster has high fluorescence quantum yield (7.38%), large Stokes shift (196 nm) and excellent tumor targeting performance, and can efficiently enter tumor cells through an LAT-1 mediated endocytosis pathway to realize high-contrast fluorescence imaging. The invention provides a novel nanoprobe for precise tumor imaging, and the nanoprobe has a relatively wide clinical application prospect.

The invention is suitable for the technical field of medical instrument auxiliary equipment, provides a tumor ablation preoperative simulation system and device, and relates to a multi-module integration system for soft tissue ablation preoperative planning, scheme simulation and doctor-patient communication. In the embodiment provided by the invention, for a target patient needing ablation treatment, tumor imaging data (such as CT and MRI) of the patient are acquired, a digital model of a tumor and peripheral tissues is reconstructed through three-dimensional modeling software, a preliminary ablation scheme is adjusted to obtain a personalized ablation scheme of the user, and a solid mold is manufactured; based on the personalized ablation scheme, simulated ablation is conducted through a human body bionic material, ablation parameters are adjusted in the ablation process according to the real-time electric field distribution state and the actual ablation range, and therefore the personalized ablation scheme is further optimized; according to the final ablation scheme of the patient, the high-light-transmittance medical glass three-dimensional mold is manufactured, and visual support is provided for doctor-patient communication. According to the system and the device, the risk that important tissues are damaged due to ablation range deviation is effectively reduced, the distribution state of ablation energy is truly fed back through a human body bionic material, and the problem that the scheme optimization efficiency is low due to the fact that the feedback time of a waiting result of a traditional simulation ablation scheme is long is solved.

The application discloses a fluorine-18 labeled indole propionic acid and a preparation method thereof, and takes 1-(2-p-toluenesulfonic acid oxyethyl)-indole propionic acid methyl ester as a precursor, which is subjected to fluorination reaction with 18 F － to obtain an intermediate 1-[ 18 F] fluorinated ethyl-indole propionic acid methyl ester. The intermediate is hydrolyzed by NaOH to obtain a target compound 1-[ 18 F] fluorinated ethyl-indole propionic acid. The compound has good chemical stability, simple preparation, good biological performance, high chemical purity, and can be used as a new PET / CT positive electron tumor imaging agent for development and popularization and application.